Advertisement

Topics

A Phase 2 Study of AZD6244 in Multiple Myeloma

2014-08-27 03:15:17 | BioPortfolio

Summary

The purpose of this study is to find out what effects, good and/or bad, AZD6244 has on participants and their multiple myeloma. In some types of cancer such as myeloma, a protein called MEK is overactive. This protein is important for cancer cells to be able to reproduce and survive. Because AZD6244 prevents MEK from working properly, it may keep cancer cells from growing and living, so cancer may shrink or its growth may slow down. There is no guarantee, however, that this will happen to the patient's cancer if they join this study.

AZD6244 is an investigational anti-cancer agent that is not approved by the U.S. Food and Drug Administration (FDA) for use in the patient's type of cancer or any other type of cancer.

Description

CYCLE 1:

DAY: Within 14 to 28 days before patients start AZD6244

- Sign Informed Consent Form

- Demographics (name, age, race, etc.)

- Get routine blood tests (and additional research blood sample if patients choose to give it).

- Medical history, smoking history, and current medications

- Physical exam

- Electrocardiogram

- Blood oxygen test

- ECHO or MUGA scan

- Chest X-Ray

- Bone survey (x-rays)

- Bone marrow biopsy and aspirate (and additional research aspirate sample if patients choose to give it)

- 24-hour urine collection

- Random urine sample (and additional research urine sample if patients choose to give it)

- Blood pregnancy test, for women of child-bearing potential

DAY: 1

- Begin taking AZD6244 capsules twice a day, about 12 hours apart. Patients keep taking AZD6244 until the end of study, unless told to stop by the study doctor or study staff.

DAY: 2

- Optional research blood and urine samples (if patients choose to give research blood and urine samples)

- Optional bone marrow procedure for aspirate (if patients choose to give research aspirate sample)

DAY: 8

- Get routine blood tests. Patients bring their study drug capsules and diary with them to study clinic.

DAY: 15

- Get routine blood tests. Patients bring their study drug capsules and diary with them to study clinic.

DAY: 22

- Get routine blood tests. Patients bring their study drug capsules and diary with them to study clinic.

Day 29 = Day 1 of next cycle

- Start the next cycle. Get routine blood tests. Patients bring their study drug capsules and diary with them to study clinic.

CYCLE 2 and FUTURE CYCLES:

DAY: Days 1 to 28 of each cycle

- Blood tests, 24-hour urine collection, review of medications and a physical exam every cycle.

- Keep taking AZD6244 twice a day if patients has no bad side effects and the cancer is not getting worse. Patient to call the study doctor or study staff if they do not know what to do.

DAY: About every 3 months

- Tests to evaluate the status of patient's cancer (any or all of the following: blood tests, urine tests, bone survey, bone marrow biopsy and aspirate).

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Multiple Myeloma

Intervention

AZD6244 hydrogen sulfate capsules

Location

H. Lee Moffitt Cancer Center & Research Institute
Tampa
Florida
United States
33612

Status

Recruiting

Source

H. Lee Moffitt Cancer Center and Research Institute

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:15:17-0400

Clinical Trials [1995 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

The purpose of this study is to test if the levels of AZD6244 in blood are affected by taking food at the same time as the capsules compared to taking capsules on an empty stomach

A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg

The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed cond...

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more e...

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

The purpose of this study is to evaluate the safety of NINLARO in participants with relapsed/refractory multiple myeloma in daily clinical practice.

Phase I Dose Escalation Trial Evaluating the Safety and Tolerability of AZD6244 Adn IMC-A12 in Subjects With Advanced Solid Malignancies

To determine the safety and tolerability of IMC-A12 in combination with AZD6244 and define the maximally tolerated dose for the combination; explore preliminary efficacy of the combination...

PubMed Articles [8576 Associated PubMed Articles listed on BioPortfolio]

Organochlorine Levels in Plasma and Risk of Multiple Myeloma: Organochlorines and risk of multiple myeloma.

To estimate the association between organochlorine pesticides and polychlorinated biphenyls (PCBs) and multiple myeloma (MM).

Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.

A 60-year-old woman diagnosed with multiple myeloma was referred for Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicula...

Severe Cytomegalovirus Enterocolitis Developing following Daratumumab Exposure in Three Patients with Multiple Myeloma.

Survival of multiple myeloma (MM) patients has improved with introduction of novel anti-myeloma agents. Myeloma has transformed into a chronic condition, accompanied with multiple relapses requiring s...

Multiple Myeloma - Current Standards in Surgical Treatment.

Multiple myeloma is a haematological blood cancer in elderly patients, in which neoplastic cell populations cause osteolytic destruction in the bone skeleton. More than 50% of all patients sustain pat...

Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.

Medical and Biotech [MESH] Definitions

An asymptomatic and slow-growing PLASMA CELL dyscrasia characterized by presence of MYELOMA PROTEINS and clonal bone marrow plasma cells without end-organ damage (e.g., renal impairment). It is distinguished from MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE by a much higher risk of progression to symptomatic MULTIPLE MYELOMA.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An envelope of loose gel surrounding a bacterial cell which is associated with the virulence of pathogenic bacteria. Some capsules have a well-defined border, whereas others form a slime layer that trails off into the medium. Most capsules consist of relatively simple polysaccharides but there are some bacteria whose capsules are made of polypeptides.

Derivatives of chondroitin which have a sulfate moiety esterified to the galactosamine moiety of chondroitin. Chondroitin sulfate A, or chondroitin 4-sulfate, and chondroitin sulfate C, or chondroitin 6-sulfate, have the sulfate esterified in the 4- and 6-positions, respectively. Chondroitin sulfate B (beta heparin; DERMATAN SULFATE) is a misnomer and this compound is not a true chondroitin sulfate.

More From BioPortfolio on "A Phase 2 Study of AZD6244 in Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Myeloma
Myeloma is a malignant disease of the bone marrow. The features are an excess of abnormal malignant plasma cells in the bone marrow, lytic deposits on an X-ray and abnormal gammaglobulin in the serum.  Symptoms include tiredness and bone pain, and t...


Searches Linking to this Trial